18 July 2026
In plain English
Five days until the FDA's peptide advisory panel votes on whether specialty pharmacies can sell peptides like BPC-157 and TB-500. The agency's own scientists recommended against all seven peptides under review, citing too little human safety data. But the panel was restocked earlier this year with members friendlier to peptide access — so the vote is genuinely uncertain. A useful benchmark surfaced today: at the same panel's 2024 hearings, every peptide that came up for a vote lost, with only 11 "yes" votes against 167 "no" votes across 13 substances. That was a different panel, though, and this one exists precisely because the old one said no. Medicare's $50-a-month weight-loss drug program has been running for 18 days with no reported problems and no enrollment data yet. Quiet day.
Signal detail
T-5. No new regulatory evidence. Quantified historical reference class: the 2024 PCAC rejected every peptide it reviewed — 11 Yes vs 167 No across 13 substances, including 0-13-0 for CJC-1295 and 0-12-1 for Ipamorelin. The present panel was reconstituted under Kennedy with pro-peptide members, which is the whole reason this forecast sits at 0.35 (65% Cat 1) rather than near the 2024 base rate (~5%). BPC-157 is the weakest of the four Day 1 candidates — fewer than 36 human subjects across 3 studies per FDA briefing docs. FDA staff recommends against. Oral presentations still absent from FDA public docket at 13+ business days past filing. Public comment closes July 22 (4 days). 5 days to resolution.
Same T-5 dynamics. The 2024 reference class argues against even a single Cat 1, but the independent variable — panel composition — has changed materially. KPV and MOTS-c have broader published literature than the 2024 candidates and are the strongest Cat 1 candidates. TB-500 weakened by PSM tumor acceleration data. The basket structure (≥2 of 4) is resilient to losing one candidate. Regulatory convergence week: PCAC July 23 + 503B comment deadline July 30. 5 days to resolution.
Month 19+ post-facility acquisition. Consumer peptide education campaign continues on Instagram. OneTwenty 13+ weeks live with zero FDA enforcement. Stock had worst week in 2 months per Yahoo Finance but BofA raised PT to $36. No new launch signals. Next catalysts: PCAC July 23, Q2 earnings August. 166 days to resolution.
No new US adverse events. Regulatory convergence week July 23–30 creates concentrated editorial window — journalists covering PCAC encounter 40% contamination statistics in FDA briefing materials and PSM's citation-ready filing documenting 78% of complications linked to contamination. 256 days to resolution.
Day 18 post-launch. No enrollment data, no operational failures, no political blowback. Consumer guide ecosystem continues to mature — CMS, AARP, Humana, Medicare Interactive all live with eligibility explainers. KFF confirms 3.8M eligible; 1M = 26% penetration in 6 months. First pharmacy claims data expected mid-to-late July. 166 days to resolution.
Zero peptide DTC affiliates in the market. GLP-1 CPA dominance $260–500 vs peptide $0 structural. CagriSema NDA pending, NOT approved — decision expected late 2026. Retatrutide NDA expected Q4 2026, approval ~late 2027. Lilly biologic classification lawsuit remanded, appeal ongoing. 166 days to resolution.
Resolutions & upcoming
No forecasts resolved. Two forecasts resolve July 23 (5 days): - `bpc157-pcac-2026` (0.35 — NOT Cat 1) - `pcac-july-multi-peptide` (0.70 — ≥2 of 4 Cat 1)
How Barque got smarter today
- Quantified 2024 PCAC base rate now available. Prior runs referenced the 2024 rejection pattern qualitatively ("every peptide lost"). Today's search surfaced the exact numbers: 11 Yes / 167 No across 13 substances. CJC-1295 0-13-0, Ipamorelin 0-12-1, Thymosin Alpha-1 4-17-0. This should be added to `historical-cases.md` as a new case — it is the most directly relevant reference class for the July 23 vote and for any future PCAC forecast.
- Panel composition vs staff framing as competing variables. The bpc157-pcac-2026 forecast at 0.35 (65% Cat 1) implicitly prices in a very high probability that the reconstituted panel overrides FDA career staff. The 2024 base rate prices Cat 1 at ~5%. The delta (5% → 65%) is entirely attributable to the Kennedy panel composition change — the largest single-variable adjustment in any active Barque forecast. Whether this is appropriately calibrated resolves in 5 days.
- Oral presentation docket absence now at 13 business days. Third consecutive brief flagging. Hardening into a pattern rather than a lag. Post-PCAC, examine whether the presentations were distributed to panelists internally or surfaced only during the hearing itself.
- CagriSema misinformation day 6. Fifth brief flagging `glp1picks-update-cagrisema-approval-confirmed` for KILL. Multiple Tier 1 sources confirm NDA pending, not approved. Operator action overdue.
- Sources sampled: FDA.gov (Tier 1), CMS.gov (Tier 1), AARP (Tier 1), KFF (Tier 1), DVM360 (Tier 1 animal), Yahoo Finance (Tier 2), Seeking Alpha (Tier 2), Simply Wall St (Tier 2), PeptideHub (Tier 2), Nootroholic (Tier 2), Drug Topics (Tier 1).